ImmunoPhotonics
4320 Forest Park Avenue
Suite 303
St. Louis
Missouri
63108
United States
Website: http://www.immunophotonics.com/
About ImmunoPhotonics
Immunophotonics is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine (inCVAX). This novel immunotherapy begins with a two injection procedure into any one accessible tumor, intended to liberate and utilize the patient’s tumor antigens to generate a systemic antitumor immune response.YEAR FOUNDED:
2009
LEADERSHIP:
Founder and CEO: Tomas Hode, PhD
COO Lu Alleruzzo, MBA
CDO (Chief Drug Dev. Officer): Joe Raker, PhD
FOLLOW IMMUNOPHOTONICS:
Tweets by Immunophotonics
5 articles with ImmunoPhotonics
-
Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors
11/10/2020
Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated solid tumors.
-
BioSpace Movers & Shakers, Oct. 9
10/9/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
10/5/2020
Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board of Directors.
-
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
-
ImmunoPhotonics Announces First Patient Dosed In A Randomized, Controlled Breast Cancer Clinical Trial For Incvax – A Novel Investigational Immuno-Oncology Therapy
8/23/2016